News | March 16, 2022
Bharat Biotech and Biofabri to develop and distribute novel TB vaccine
MTBVAC is a global public-private project that will be a milestone in the field of vaccinology
MTBVAC is a global public-private project that will be a milestone in the field of vaccinology
Under the agreement, both companies will conduct collaborative research utilizing NuclixBio's proprietary circular mRNA platform named 'ringRNA’ to develop novel mRNA therapeutics that can generate PharmAbcine's antibodies
A growing portfolio of chemicals is part of a larger quality management system that sets new standards in bioprocessing
Aducanumab collaboration to convert from Eisai sharing of global profits and losses to a global royalty arrangement, effective January 1, 2023
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
These new chemical entities are covered by composition of matter patent applications. Financial terms of the deal were not disclosed
The study met its primary endpoint and showed equivalent efficacy and a comparable safety profile
The Gujarat Biotechnology policy released last month has made radical changes to position the state as a biotechnology hub. It already has a thriving ecosystem of pharma companies and varied suppliers
Selvax's goal is to develop safe, effective and immunological-based treatments for a range of hard-to-treat solid tumours
Nulibry is approved by the U.S. Food and Drug Administration (USFDA) to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening paediatric genetic disorder
Subscribe To Our Newsletter & Stay Updated
